Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...

Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

We carried out a thorough and complete review of the husbandry and management practices in cooperation with the floor supervisor and animal caretakers and ruled out chemical, physical, solar and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with bullous pemphigoid treated with IL-2 had ...

Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...

Dear Dr. Roach: I was recently diagnosed with bullous pemphigoid, and the dermatologist recommended 10 mg prednisone. I was hoping you could recommend a different medication. — R.M. Answer: Bullous ...